Drug Policy Polling 2026: Marijuana, Opioids & the Fentanyl Crisis

Public support for marijuana legalization has more than doubled in 24 years, reaching majority status around 2013 and continuing to climb. The shift reflects generational replacement, changing social norms, and the visible evidence of legal marijuana states operating without the catastrophic consequences opponents predicted.

Source: Gallup annual survey on marijuana legalization, 2000–2024.

Marijuana legalization is unusually cross-partisan in its support profile — it is actually more popular among Independents than among Democrats, and has broken 45% even among Republicans, making it a rare issue where the parties are not cleanly sorted.

Source: Gallup 2024. Question: "Do you think the use of marijuana should be made legal, or not?"

The opioid epidemic has claimed over 500,000 American lives since 1999. The crisis has evolved through three distinct waves — and 2026 finds the country still in the third:

72% of Americans describe the opioid crisis as a major problem. The issue polls as bipartisan — rural, white, working-class communities that are core Republican constituencies have been among the hardest hit, making this a rare area where both parties express urgency.

Fentanyl has become deeply embedded in immigration and border policy debates. The Trump administration has repeatedly linked fentanyl trafficking to the southern border and used it as a justification for military deployments, cartel designations as foreign terrorist organizations, and tariffs on Mexico.

Polling on fentanyl enforcement shows strong support for criminal penalties: 70% of Americans support criminal penalties for fentanyl trafficking even if that includes life sentences — a notably punitive stance compared to polling on other drug offenses. This crosses partisan lines more than marijuana legalization; even many legalization supporters favor harsh penalties for fentanyl distribution.

Harm reduction advocates argue that criminalization alone cannot address addiction, pointing to needle exchange programs, naloxone distribution, and safe injection sites as evidence-based interventions. 55% of Americans support safe injection sites as a harm reduction strategy. However, the Trump administration has taken a more enforcement-heavy posture, scaling back federal harm reduction support and emphasizing supply-side enforcement.

In a historic administrative action, President Biden's Drug Enforcement Administration (DEA) proposed reclassifying marijuana from Schedule I to Schedule III under the Controlled Substances Act in 2024. This was the most significant federal marijuana policy change since the Controlled Substances Act was enacted in 1970. 61% of Americans support the Schedule III reclassification specifically — including many who do not support full federal legalization — because it is seen as a practical, evidence-based step rather than a wholesale policy reversal.

What Schedule I means: Drugs classified as Schedule I are defined as having no accepted medical use and a high potential for abuse — putting marijuana in the same category as heroin. This classification has blocked federally funded medical research for decades and creates conflicts between state-legal marijuana businesses and federal banking, taxation, and employment law.

What Schedule III would mean: Schedule III drugs (like ketamine, anabolic steroids, and some prescription medications) are recognized as having accepted medical uses with moderate-to-low potential for abuse. Reclassification would not legalize marijuana nationally but would ease research restrictions, reduce tax burdens on cannabis businesses (by allowing them to deduct expenses under Section 280E of the tax code), and reduce the contradiction between state and federal law.

As of 2026, the reclassification remained in a federal regulatory review process. The Trump administration's position on whether to continue, halt, or reverse the rulemaking remained one of the open questions in federal marijuana policy.

The gap between federal prohibition and state-level legalization has created a patchwork system with significant practical consequences:

• 24 states + D.C. with recreational marijuana: Includes California, Colorado, New York, Illinois, Michigan, Arizona, New Jersey, and most of New England. These states have collectively generated billions in tax revenue and have not seen the social catastrophes predicted by opponents.
• 38 states with medical marijuana: Only Idaho, Wyoming, Kansas, and South Carolina remain without any form of legal medical access.
• Banking problem: Because marijuana is still federally illegal, most banks refuse to serve cannabis businesses. This forces many dispensaries to operate cash-only, creating safety risks. Congress has repeatedly failed to pass the SAFE Banking Act, which would resolve this conflict.
• Employment conflict: Workers can legally use marijuana in recreational states but still be fired (or not hired) by employers who require drug tests aligned with federal standards — a growing source of legal conflict.
• Interstate commerce: Despite state legalization, transporting marijuana across state lines remains a federal crime, preventing interstate commerce even between two legal states.

Mandatory minimum sentencing laws require judges to impose predetermined prison terms for drug offenses regardless of individual circumstances. Enacted primarily in the 1980s and 1990s as part of the "War on Drugs," these laws have been widely criticized as disproportionately affecting Black and Hispanic defendants, filling prisons with low-level offenders, and failing to deter drug use or trafficking.

62% of Americans support reducing mandatory minimum sentences for drug offenses — one of the highest levels of bipartisan agreement on criminal justice reform. The First Step Act (2018), signed by President Trump in his first term, reduced some mandatory minimums for certain drug offenses and is one of the few pieces of criminal justice legislation with genuine cross-partisan support. The Trump second term has not expanded on First Step Act reforms; instead, the DOJ has returned to more aggressive charging guidelines.

The mandatory minimum debate intersects with the racial justice debate in ways that complicate partisan alignment. Conservative supporters of reduced mandatory minimums typically frame it as government overreach and judicial discretion; liberal supporters frame it as racial justice and ending mass incarceration. Both framings point to the same policy outcome, creating unusual cross-ideological agreement at the polling level even when the political coalition building at the legislative level is contentious.

Sources: Gallup 2023, Pew Research Center, KFF Health Tracking Poll 2024. The fentanyl enforcement and opioid treatment figures show rare bipartisan alignment: both poll above 75% across party lines.